Qiming U.S. Ventures Management

Latest statistics and disclosures from Qiming U.S. Ventures Management's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are Icosavax, KRRO, TRML, HLVX, Jasper Therapeutics, and represent 96.56% of Qiming U.S. Ventures Management's stock portfolio.
  • Added to shares of these 2 stocks: KRRO (+$18M), TRML (+$17M).
  • Started 2 new stock positions in TRML, KRRO.
  • Reduced shares in these 1 stock: Talaris Therapeutics (-$8.2M).
  • Sold out of its position in Talaris Therapeutics.
  • Qiming U.S. Ventures Management was a net buyer of stock by $26M.
  • Qiming U.S. Ventures Management has $109M in assets under management (AUM), dropping by 44.99%.
  • Central Index Key (CIK): 0001909617

Tip: Access up to 7 years of quarterly data

Positions held by Qiming U.S. Ventures Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Qiming U.S. Ventures Management

Qiming U.S. Ventures Management holds 8 positions in its portfolio as reported in the December 2023 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Icosavax 50.7 $55M 3.5M 15.76
 View chart
Korro Bio (KRRO) 16.2 $18M NEW 368k 47.93
 View chart
Tourmaline Bio (TRML) 15.4 $17M NEW 642k 26.18
 View chart
Hillevax (HLVX) 8.2 $9.0M 559k 16.05
 View chart
Jasper Therapeutics 6.2 $6.7M 8.5M 0.79
 View chart
Ventyx Biosciences (VTYX) 1.6 $1.7M 686k 2.47
 View chart
Elevation Oncology (ELEV) 1.2 $1.3M 2.4M 0.54
 View chart
Kezar Life Sciences (KZR) 0.7 $785k 829k 0.95
 View chart

Past Filings by Qiming U.S. Ventures Management

SEC 13F filings are viewable for Qiming U.S. Ventures Management going back to 2021